Biomarker Strategies Logo


 

BioMarker Strategies has developed the proprietary and recently patented SnapPath Cancer Diagnostics System for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. Our mission is to make personalized medicine more of a reality for these patients.

SnapPath® is unique in automating and standardizing functional ex vivo profiling to capture the dynamic and predictive signaling information available only from live solid tumor cells.

Our PathMAP® Functional Signaling Profiles, created using the SnapPath® system, represent a new class of biomarker tests that are highly predictive of individual response to targeted treatments for solid tumors, because they are based on information available only from live cells.

Our business development efforts are directed toward entering into funded collaborations with companies developing targeted therapies for patients with solid tumors.

The capabilities of SnapPath® and the Functional Profiles it enables are available for Research Use in preclinical studies in tumorgraft and other model systems, and in early clinical studies to assess pharmacodynamic changes in the solid tumors of individual patients.

BioMarker Strategies
15601 Crabbs Branch Way
Rockville, MD 20855

Phone: 410-522-1008
Fax: 410-522-1009
info@biomarkerstrategies.com

 



Recent Headlines
October 3, 2017 - BioMarker Strategies Announces Phase I National Cancer Institute Grant to Develop Companion Diagnostic to Identify Patients with Head and Neck Cancer Who Are Most Likely to Respond to Treatment with Cetuximab. Press Release
September 25, 2017 - BioMarker Strategies Announces United States Patent for PathMAP Functional Signaling Profile Technology. Press Release
September 11, 2017 - BioMarker Strategies Announces Phase II National Cancer Institute Grant to Continue Development of Companion Diagnostic Test to Help Select Optimal Therapy for Patients with Non-Small Cell Lung Cancer. Press Release
August 31, 2017 - BioMarker Strategies Announces Two New Patents Granted in Japan, Covering the Company’s Core Diagnostics Technologies for Solid Tumor Cancers. Press Release
July 19, 2017 - BioMarker Strategies Announces Issuance of Key Patent in Europe Covering the Company’s PathMAP® Functional Signaling Profile Technology. Press Release


2017 BioMarker Strategies